Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Clynes RA, Towers TL, Presta LG, Ravetch JV.

Nat Med. 2000 Apr;6(4):443-6.

PMID:
10742152
2.

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.

Cancer Res. 2007 Sep 15;67(18):8882-90. Erratum in: Cancer Res. 2008 Sep 15;68(18):7692. Vijh, Sujata [added].

3.

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.

Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E.

Breast Cancer Res. 2011;13(6):R123. doi: 10.1186/bcr3069. Epub 2011 Nov 30.

4.

Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.

Stockmeyer B, Elsässer D, Dechant M, Repp R, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T.

J Immunol Methods. 2001 Feb 1;248(1-2):103-11.

PMID:
11223072
5.

V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.

Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, Moriyasu F, Nieda M, Nicol AJ.

Int J Cancer. 2008 Jun 1;122(11):2526-34. doi: 10.1002/ijc.23365. Erratum in: Int J Cancer. 2011 Dec 1;129(11):2761. Fai-So, Hang [corrected to So, Hang-Fai].

6.

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ.

J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11.

7.

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S.

Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517.

8.
9.

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.

Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA.

Cancer Res. 2003 Oct 1;63(19):6453-7.

10.

Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.

Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P.

MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570.

11.

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, Baum A, Lamche H, Küpcü Z, Jacobi A, Müller S, Hirt U, Adolf GR, Borges E.

Blood. 2011 Oct 13;118(15):4159-68. doi: 10.1182/blood-2011-04-351932. Epub 2011 Jul 27.

12.

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ.

Cancer Res. 2003 Sep 1;63(17):5595-600.

13.

Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.

Funakoshi S, Longo DL, Murphy WJ.

J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):93-101.

PMID:
8732692
14.

Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.

Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.

J Immunother. 2009 Jul-Aug;32(6):622-31. doi: 10.1097/CJI.0b013e3181ab23f1.

PMID:
19483647
15.

Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.

Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, Oppezzo P, Pritsch O, Osinaga E, Amigorena S.

Cancer Res. 2011 Aug 1;71(15):5134-43. doi: 10.1158/0008-5472.CAN-10-4222. Epub 2011 Jun 22.

16.

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.

Cancer Res. 2008 Oct 1;68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268.

17.

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T.

J Immunol. 2000 Nov 15;165(10):5954-61.

19.

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.

Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, Zhukovsky EA.

Blood. 2010 Oct 21;116(16):3004-12. doi: 10.1182/blood-2010-01-265280. Epub 2010 Jul 8.

20.

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.

Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX.

Cancer Res. 2010 Jun 1;70(11):4481-9. doi: 10.1158/0008-5472.CAN-09-3704. Epub 2010 May 18.

Supplemental Content

Support Center